AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: AMY REEVES
Plenty of companies have faced the challenge of coming out of slumps.
But Bio-Rad Laboratories Inc. has a different kind of task: How do you follow up a stellar year?
Last year, the biomedical firm soared after it came out with two new test kits for bovine spongiform encephalopathy, better known as "mad cow disease." Two other firms, both European and privately held, also made such tests.
But 43-year-old Bio-Rad was the first established name to get in the game. Soon it had captured more than two-thirds of the market.
Wall Street hadn't much noticed the thinly traded stock until then. But creating a test for such a famous disease changed that. Over the course of the year, the stock price roughly doubled.
Now comes the letdown.